News for Healthier Living

A Roadmap for Smarter TMB-Guided Immunotherapy

Tumor mutational burden, or TMB, has long been viewed as a promising way to identify which patients may benefit from cancer immunotherapy, but its real-world use has been slowed by inconsistent testing and interpretation. A new expert consensus now brings needed order to that complexity by defining what TMB is, how it should be measured, how results should be reported, and where its clinical value is strongest. Rather than treating TMB as a single number with universal meaning, the consensus frames it as a context-dependent biomarker that must be interpreted through tumor type, testing platform, and therapeutic setting. That shift could help turn an often confusing laboratory metric into a more reliable guide for treatment decisions.

March 25, 2026


March 25 2026

March 24 2026

March 23 2026

March 22 2026

March 21 2026

March 20 2026

March 19 2026

March 18 2026

March 17 2026

March 16 2026

March 15 2026

March 14 2026

March 13 2026

March 12 2026

March 11 2026